Anabolic steroidAndrogenTestosterone esterInjectable

Testosterone Hexahydrobenzylcarbonate

Also known as Test hexa · Testosterone cyclohexylmethylcarbonate

Written by enwyReviewed 5 Aug 20261 sources0 comments

A long-acting testosterone ester using the hexahydrobenzylcarbonate (cyclohexylmethyl carbonate) group, the same carbonate ester used in the veterinary trenbolone product Parabolan. Applied to testosterone it would give a slow, extended depot release comparable to enanthate or slightly longer, allowing infrequent dosing. It has no pharmaceutical history and is essentially a theoretical/underground testosterone ester.

01 Overview

Carbonate esters like hexahydrobenzylcarbonate slow steroid release similarly to long carboxylic acid esters. This particular ester is famous on trenbolone (Parabolan) but has no established use on testosterone. A testosterone hexahydrobenzylcarbonate would behave as a long-acting testosterone depot, releasing plain testosterone after hydrolysis.

Since no pharmaceutical or veterinary product exists, there are no pharmacokinetic data specific to this ester of testosterone. Any effects and side effects are simply those of testosterone with an extended, slow release profile. It is included for completeness in the injectable testosterone-ester family and should be considered uncharacterised in humans.

02 Mechanism

The carbonate ester is slowly hydrolysed to release testosterone, which activates the androgen receptor to drive anabolism and aromatises to estradiol.

03 Dosing

Tier	Dose	Route	Notes
TRT-equivalent	100–200 mg/wk	IM	Extrapolated; long ester allows weekly or less frequent dosing.
Enhancement	300–500 mg/wk	IM	Anecdotal; no validated protocol.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Increased lean mass and strengthStandard testosterone anabolic effect once the ester is cleaved.	Dose-dependent	Clinical
Stable long-duration levelsA long carbonate ester would allow infrequent injections.	Extended release	Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence
Estrogenic effectsAromatisation to estradiol can cause gynecomastia and water retention.	Moderate	Common at higher doses	Clinical
PolycythemiaRaised hematocrit increasing thrombotic risk.	Moderate	Common with chronic use	Clinical
HPTA suppressionSuppression of natural testosterone and fertility.	Severe	Universal	Clinical

06 Legal status

United States

Schedule III controlled substance

as of Jan 2026

07 References

Testosterone esters: structure and release kinetics (review)Andrology review

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.